Catalyst
Monitor the FDA's decision on giredestrant's approval by November 30, 2026, and ongoing results from the lidERA study regarding overall survival data.
Humanexa recommends Escalate.
Date
June 16, 2026
Phase
N/A
Status
watch
Signal score
9.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.